Safety study of new inclisiran formulation for cholesterol
This trial tests a new version of inclisiran, a cholesterol-lowering medicine, to see if it is safe and works well. The study compares it to the current version. You may qualify if you have moderately high cholesterol but have never taken cholesterol medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–60 years old and in good health with no serious medical conditions
- Fasting LDL cholesterol ("bad" cholesterol) between 100–189 mg/dL—moderately elevated but not extremely high
- Fasting triglycerides (another blood fat) below 400 mg/dL
- Never taken statin drugs or other cholesterol-lowering medications or supplements
- Body mass index (BMI) between 18–35, meaning healthy weight range
- If female, must not be able to become pregnant or must use reliable birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
This trial tests if adding inclisiran to your current statin can reduce dangerous, rupture-prone plaque in your heart arteries. It may help if you have a moderate blockage with thin-cap plaque and your LDL cholesterol stays high despite statins.
This study tests a new investigational drug called MWX203, given alone or with another medicine (inclisiran), to lower both 'bad' cholesterol (LDL) and triglycerides in people with mixed dyslipidemia. The goal is to see if the combination is safe and works better than statins alone.
Hear when a new Inclisiran Formulation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.